OBIOOrchestra BioMed Holdings, Inc.
$5.59+57% 1Y
$5.59
$3.4952 weeks$6.36
Is the price fair?
What OBIO's price assumes
Orchestra BioMed Holdings, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 8.61× revenue.
8.61
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 14.3
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 14.3
- EV / EBIToperating margin −181%: the multiple describes the denominator
- not meaningful
- Market capitalisation60.1 million shares, counted Aug 6, 2026
- $336M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.